Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.48 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17518890 | 0.90 | FFAR1 (1.00) | FFAR1CYP26A1CYP26B1 | |
| SCHEMBL19166171 | 0.88 | FFAR1 (1.00) | FFAR1MAOBMAOACYP26A1CYP26B1 | |
| SCHEMBL1745020 | 0.87 | FFAR1 (0.77) | FFAR1MAOBMAOACYP26A1CYP26B1 | |
| SCHEMBL22450982 | 0.85 | FFAR1 (0.74) | FFAR1MAOBMAOACYP26A1CYP26B1 | |
| SCHEMBL19166584 | 0.83 | FFAR1 (1.00) | FFAR1MAOBMAOACYP26A1CYP26B1 | |
| SCHEMBL19166194 | 0.83 | FFAR1 (1.00) | FFAR1CYP26A1CYP26B1 | |
| SCHEMBL1747131 | 0.82 | FFAR1 (0.73) | FFAR1MAOBMAOA | |
| SCHEMBL17518896 | 0.80 | FFAR1 (1.00) | FFAR1MAOBMAOACYP26A1CYP26B1 | |
| SCHEMBL17495222 | 0.80 | FFAR1 (0.77) | FFAR1MAOBMAOACYP26A1CYP26B1 | |
| SCHEMBL22450988 | 0.79 | FFAR1 (0.69) | FFAR1MAOBMAOACYP26A1CYP26B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177285-B1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3177285-B1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10100042-B2 | [5,6]—fused bicyclic antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170210727-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210727-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210727-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210727-A1 | [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | GPR119, GPR55, GPR65 | FFAR1 13/4885MAOB 4321/4885MAOA 4333/4885 |
| US-10100042-B2 | [5,6]—fused bicyclic antidiabetic compounds | GPR119, GPR55, GPR65 | FFAR1 14/4885MAOB 4355/4885MAOA 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.